Have a feature idea you'd love to see implemented?
Let us know!
GERN Geron Corp
Price (delayed)
$3.89
Market cap
$2.34B
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$0.36
Enterprise value
$2.31B
Geron is a late-stage clinical biopharmaceutical company focused on the development and potential commercialization of a first-in-class telomerase inhibitor, imetelstat, in hematologic myeloid malignancies. The Company currently is conducting two
Highlights
The revenue has soared by 164% from the previous quarter
The company's gross profit has surged by 161% QoQ
Geron's equity has decreased by 11% from the previous quarter but it has increased by 2.8% YoY
Geron's EPS has decreased by 2.9% from the previous quarter but it has increased by 2.7% YoY
GERN's debt has surged by 56% year-on-year
The quick ratio has contracted by 31% YoY and by 2.2% from the previous quarter
Key stats
What are the main financial stats of GERN
Market
Valuations
Earnings
Shares outstanding
602.8M
Market cap
$2.34B
Enterprise value
$2.31B
Price to earnings (P/E)
N/A
Price to book (P/B)
7.52
Price to sales (P/S)
1,852.65
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
1,685.25
Revenue
$1.37M
EBIT
-$208.41M
EBITDA
-$207.2M
Free cash flow
-$208.59M
Per share
Balance sheet
Liquidity
EPS
-$0.36
Free cash flow per share
-$0.32
Book value per share
$0.52
Revenue per share
$0
TBVPS
$0.69
Total assets
$449.4M
Total liabilities
$142.7M
Debt
$87.04M
Equity
$306.7M
Working capital
$269.77M
Debt to equity
0.28
Current ratio
3.61
Quick ratio
3.54
Net debt/EBITDA
0.15
Margins
Efficiency
Dividend
EBITDA margin
-15,091.1%
Gross margin
98.8%
Net margin
-15,990.6%
Operating margin
-16,559.9%
Return on assets
-50.5%
Return on equity
-73.8%
Return on invested capital
-68.4%
Return on capital employed
-60.3%
Return on sales
-15,179.3%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
GERN stock price
How has the Geron stock price performed over time
Intraday
-1.52%
1 week
-7.16%
1 month
-17.41%
1 year
113.74%
YTD
84.36%
QTD
-14.32%
Financial performance
How have Geron's revenue and profit performed over time
Revenue
$1.37M
Gross profit
$1.36M
Operating income
-$227.37M
Net income
-$219.55M
Gross margin
98.8%
Net margin
-15,990.6%
The revenue has soared by 164% from the previous quarter
The company's gross profit has surged by 161% QoQ
GERN's net margin has surged by 59% since the previous quarter and by 58% year-on-year
The operating margin has soared by 59% since the previous quarter and by 57% year-on-year
Growth
What is Geron's growth rate over time
Valuation
What is Geron stock price valuation
P/E
N/A
P/B
7.52
P/S
1,852.65
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
1,685.25
Geron's EPS has decreased by 2.9% from the previous quarter but it has increased by 2.7% YoY
The P/B is 82% above the 5-year quarterly average of 4.2 and 39% above the last 4 quarters average of 5.5
Geron's equity has decreased by 11% from the previous quarter but it has increased by 2.8% YoY
The revenue has soared by 164% from the previous quarter
The P/S is 49% below the last 4 quarters average of 3701.3 but 6% above the 5-year quarterly average of 1776.6
Efficiency
How efficient is Geron business performance
Geron's ROS has soared by 59% from the previous quarter and by 58% YoY
GERN's ROE is up by 12% year-on-year but it is down by 8% since the previous quarter
Geron's ROIC has decreased by 11% from the previous quarter but it has increased by 3.5% YoY
The ROA has grown by 7% YoY but it has contracted by 7% from the previous quarter
Dividends
What is GERN's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for GERN.
Financial health
How did Geron financials performed over time
The quick ratio has contracted by 31% YoY and by 2.2% from the previous quarter
GERN's current ratio is down by 31% year-on-year
GERN's debt is 72% smaller than its equity
GERN's debt has surged by 56% year-on-year
GERN's debt to equity is up by 47% YoY and by 12% QoQ
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.